| Pharmaceutical Information |
| Drug Name |
Tocilizumab |
| Drug ID |
BADD_D02234 |
| Description |
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.[A193281] It is currently being investigated to treat severely ill patients with COVID-19.[A193278,L12837,L12843]
Tocilizumab was granted FDA approval on 8 January 2010.[L12789] |
| Indications and Usage |
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.[L12789] |
| Marketing Status |
approved |
| ATC Code |
L04AC07 |
| DrugBank ID |
DB06273
|
| KEGG ID |
D02596
|
| MeSH ID |
C502936
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D08HPZ
|
| NDC Product Code |
50242-139; 50242-157; 50242-158; 50242-138; 50242-137; 50242-141; 71124-0019; 50242-136; 82143-004; 50242-143; 50242-135 |
| UNII |
I031V2H011
|
| Synonyms |
tocilizumab | atlizumab | monoclonal antibody, MRA | BAT-1806 | BAT1806 | MSB11456 | MSB-11456 | RG-1569 | R-1569 | RO-4877533 | Actemra | Roactemra | RHPM-1 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
375823-41-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
